Gilead exercised an option license on a Kymera Therapeutics protein-degrading program targeting CDK2, while Roche expanded its protein-degrader ambitions via a new collaboration with C4 Therapeutics focused on degrader-antibody drug conjugates (DACs). The Gilead move gives the pharma another lever in oncology beyond traditional small molecules and antibody payloads, using targeted degradation to disrupt cancer drivers. Roche’s deal couples degrader specificity and catalytic activity with ADC-style delivery, underscoring how both companies are moving to hybrid modalities as oncology targets remain difficult for single-agent mechanisms.